精准肝脏外科时代肝癌多学科治疗*

doi:10.3969/j.issn.1672-5069.2015.02.004

摘要/Abstract

Key words: Hepatocellular carcinoma, Precise liver surgery, Multidisciplinary treatments

荚卫东. 精准肝脏外科时代肝癌多学科治疗^*[J]. 实用肝脏病杂志, 2015, 18(2): 120-123.

Jia Weidong. Multidisciplinary treatments for patients with hepatocellular carcinoma in the era of precise liver surgery[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 120-123.

[1] 荚卫东.精准肝切除治疗肝细胞癌关键技术. 中国普通外科杂志,2014,23（1）:1-5.
[2] 董家鸿,黄志强. 倡导精准肝脏外科重现普罗米修斯神话. 中华消化外科杂志,2010,9（1）:4-5.
[3] 许戈良,荚卫东,李建生,等. 应用精细肝脏外科理念治疗原发性肝癌53例. 世界华人消化杂志,2010,18（17）:1824-1828.
[4] 仇毓东,朱新华,徐庆祥,等. 精准肝切除术治疗原发性肝癌的疗效评价. 中华消化外科杂志,2010,9（1）:1-3.
[5] 中华消化外科杂志编辑部. 精准肝脏外科专题讨论. 中华消化外科杂志,2014,13（6）:419-430.
[6] Fan ST. Precise hepatectomy guided by the middle hepatic vein. Hepatobiliary Pancreat Dis Int,2007,6（4）:430-434.
[7] 许戈良. 精细肝脏外科的发展. 国际外科学杂志,2008,35（2）:73-75.
[8] 董家鸿,黄志强.精准肝切除—21世纪肝脏外科新理念. 中华外科杂志,2009,47（21）:1601-1605.
[9] 马金良,李建生, 荚卫东, 等. 多层螺旋CT三维重建在肝脏肿瘤手术中的应用. 实用肝脏病杂志,2007,10（5）:296-297.
[10] 孙逊,许戈良,荚卫东,等. 3D虚拟手术规划系统在精准肝切除治疗肝细胞癌的临床应用. 国际外科学杂志,2014,41（8）:537-540.
[11] 李光耀,荚卫东,许戈良,等. 精准右半肝联合尾状叶肿瘤切除术. 中华消化外科杂志,2014,13（9）:726-729.
[12] 荚卫东,许戈良,马金良,等. 超声吸引刀结合单极电凝在原发性肝癌肝切除中的应用.临床外科杂志,2009,17（12）:824-827.
[13] 荚卫东,刘文斌,许戈良,等. 精细肝切除治疗原发性肝癌术后并发症的原因和防治. 国际外科学杂志,2012,39（4）:246-249.
[14] 荚卫东,乔晓斐. 精准肝脏外科时代无痛病房建设. 中华消化外科杂志,2014,13（6）:415-418.
[15] 荚卫东. 加速康复外科在精准肝脏外科中的应用.中华消化外科杂志,2015,14（1）:25-28.
[16] 许戈良, 荚卫东. 肝切除术中肝脏功能的影响因素及其评估.世界华人消化杂志,2010,18（35）:3721-3723.
[17] 苏昭然,荚卫东,许戈良,等. 肝切除术中吲哚青绿排泄试验预测术后肝功能不全的临床研究.中华普通外科杂志,2011,17（7）:618-620.
[18] NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancer. V2.2012：46.
[19] Llovet JM,Ducreux M,Lencioni R,et al. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma. J Hepatology,2012,56（4）：908-943.
[20] Morris-Stiff G,Gomez D,de Liguori Carino N,et al. Surgical management of hepatocellular carcinoma:is the jury still out? Surg Oncol,2009,18（4）:298-321.
[21] Iwadou S,Nouso K,Kuwaki K,et al. Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int,2010,30（7）:1027-1032.
[22] Forner A,Reig ME,de Lope CR,et al. Current strategy for staging and treatment:the BCLC update and future prospects. Semin Liver Dis,2010,30（1）:61-74.
[23] Yin L,Li H,Li AJ,et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria:a RCT. J Hepatol,2014,61（1）:82-88.
[24] Llovet JM,Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol,2008,48（Suppl 1）:20-37.
[25] Choi KK,Kim SH,Choi SB,et al. Portal venous invasion:the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol,2011,26（11）:1646-1651.
[26] Demicheli R,Retsky MW,Hrushesky WJ,et al. The effects of surgery on tumor growth:a century of investigations. Ann Oncol,2008,19（11）:1821-1828.
[27] Sun YF,Xu Y,Yang XR,et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology,2013,57（4）:1458-1468.
[28] Li CX,Wong BL,Ling CC,et al. A novel oxygen carrier “YQ23” suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. BMC Cancer,2014,27（14）:293.
[29] 肝细胞癌抗病毒治疗专家组. HBV/HCV相关性肝细胞癌抗病毒治疗专家共识. 中华肝脏病杂志,2014,22（5）:321-325.
[30] Sasaki A,Iwashita Y,Shibata K,et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol,2006,32（7）:773-779.
[31] Ren ZG,Lin ZY,Xia JL,et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor:a retrospective control study. World J Gastroenterol,2004,10（19）:2791-2794.
[32] Lammer J,Malagari K,Vogl T,et al. Prospective randomized study of oxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:Results of the PRECISION v study. Cardiovasc Intervent Radiol,2010,33（1）:41-52.
[33] Hasegawa K,Takayama T,Ijichi M,et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology,2006,44（4）:891-895.
[34] Xia Y,Qiu Y,Li J,et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection:a randomized controlled trial. Ann Surg Oncol,2010,17（12）:3137-3144.
[35] Qin S,Bai Y,Lim HY,et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol,2013,31（28）:3501-3508.
[36] Zhong JH,Li H,Li LQ,et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma:a systematic review of randomized trials. Eur J Surg Oncol,2012,38（4）:286-295.
[37] Ji J,Shi J,Budhu A,et al. MicroRNA expression,survival,and response to interferon in liver cancer. N Engl J Med,2009,361（15）:1437-1447.
[38] Mazzaferro V,Romito R,Schiavo M,et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology,2006,44（6）:1543-1554. [39] 张传海,荚卫东. 索拉非尼在肝癌治疗中的应用. 临床药学治疗杂志,2012,10（3）:24-26.
[40] Wilhelm SM,Carter C,Tang L,et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res,2004,64（19）：7099-7109.
[41] 荚卫东,刘文斌. 高危复发因素肝细胞癌肝切除术后综合治疗. 世界华人消化杂志,2013,21（30）:3183-3189.

精准肝脏外科时代肝癌多学科治疗^*

Multidisciplinary treatments for patients with hepatocellular carcinoma in the era of precise liver surgery

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[2]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[5]	杨富存, 尚怀学, 盖永浩. 钆塞酸二钠增强磁共振扫描诊断肝脏局灶性病变研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 577-580.
[6]	彭新健, 肖玉辉, 许斯鼎, 石荣跃, 王耀政, 王瑜琳. 放射性肝损伤患者肝脏磁共振扩散加权成像表现特征分析[J]. 实用肝脏病杂志, 2019, 22(3): 373-376.
[7]	乔志忠. 超声造影定量分析鉴别肝脏局灶性结节性增生与原发性肝癌初步探讨[J]. 实用肝脏病杂志, 2019, 22(3): 421-424.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	幸奠奎,程婧. ¹⁸F-FDG PET/CT检查指标预测肝细胞癌微血管侵犯临床价值研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 252-254.
[11]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[12]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.
[13]	王朝霞,关珂,付三仙,王慧杰. 肠内肠外联合营养支持治疗肝细胞癌患者围术期临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 272-275.
[14]	赵西太综述,聂青和审校. 循环microRNA早期诊断肝细胞癌研究现状及方法学探讨[J]. 实用肝脏病杂志, 2019, 22(2): 297-300.
[15]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.